TAISHO PHARMACEUTICAL TO LAUNCH OTC-SWITCHED ZADITEN NASAL SOLUTION
Taisho Pharmaceutical (TSE: 4535) announced on August 3 that it has received approval from the Ministry of Health, Labor and Welfare for an OTC-switched version of Zaditen Nasal Solution, an antiallergic agent developed by Novartis Pharma. Taisho will distribute OTC-switched Zaditen as its Pabron series through pharmacies across Japan while Novartis Pharma will import it. Containing ketotifen fumarate as a main ingredient, the product helps alleviate nasal allergy symptoms due to pollen and house-dust mites.
Japan Corporate News Network (http://www.japancorp.net/Article.Asp?Art_ID=10621)